Hsa-miR-155-5p expression in primary breast tissue may have the potential for prediction of breast cancer brain recurrence: results from the multi-institutional exploratory cohort study
Hsa-miR-155-5p expression in untreated primary breast tissue may be a valuable biomarker for predicting BCBR. A personalized escalation strategy is expected to be helpful in conquering brain metastases.
Authors
- Takahiro Ochiya (ORCID: https://orcid.org/0000-0002-0776-9918)
- Yoichi Koyama (ORCID: https://orcid.org/0000-0001-7435-1346)
- Kimito Yamada (ORCID: https://orcid.org/0000-0002-5443-7078)
- Kazutaka Narui (ORCID: https://orcid.org/0000-0002-0135-5001)
- Masako Muguruma (ORCID: https://orcid.org/0009-0006-2269-0411)
- Yusuke Yoshioka
- Akimitsu Yamada (ORCID: https://orcid.org/0000-0003-3006-0648)
- Shunichiro Orihara (ORCID: https://orcid.org/0000-0003-0168-1250)
- Takashi Ishikawa (ORCID: https://orcid.org/0000-0003-3450-4533)
- Yoshiya Horimoto (ORCID: https://orcid.org/0000-0001-8935-0768)
- Shinya Yamamoto (ORCID: https://orcid.org/0000-0002-8083-5387)
- Akiko Kogure
- Hiroshi Kaise (ORCID: https://orcid.org/0000-0002-6638-783X)
Institutions
- Tokyo Medical University (JP)
- Yokohama City University Medical Center (JP)
- Juntendo University (JP)
- Tokyo Medical University Hachioji Medical Center (JP)
- Tokyo Medical University Hospital (JP)
- Yokohama Rosai Hospital (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1186/s13058-025-02123-5
- Citations
- 1
- Primary Topic
- MicroRNA in disease regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- Taiho Pharmaceutical
- Chugai Pharmaceutical